inclusion criteria: 1. willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under international conference on harmonization (ich) e6(r2) 4.8.15 emergency use provisions as deemed necessary by the investigator (age ≥18) prior to performing study procedure. 2. aged ≥ 18 years. 3. severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by polymerase chain reaction (pcr) test ≤ 4 days before randomization. 4. currently hospitalized. 5. peripheral capillary oxygen saturation (spo2) ≤ 94% or requiring supplemental oxygen on screening.

inclusion criteria: 1. willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under international conference on harmonization (ich) e6(r2) 4.8.15 emergency use provisions as deemed necessary by the investigator (age ≥18) prior to performing study procedure. 2. aged ≥ 18 years. 3. severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by polymerase chain reaction (pcr) test ≤ 4 days before randomization. 4. currently hospitalized. 5. peripheral capillary oxygen saturation (spo2) ≤ 94% or requiring supplemental oxygen on screening.

inclusion criteria: willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under international conference on harmonization (ich) e6(r2) 4.8.15 emergency use provisions as deemed necessary by the investigator (age ≥18) prior to performing study procedure. aged ≥ 18 years. severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by polymerase chain reaction (pcr) test ≤ 4 days before randomization. currently hospitalized. peripheral capillary oxygen saturation (spo2) ≤ 94% or requiring supplemental oxygen on screening.

inclusion criteria: willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under international conference on harmonization (ich) e6(r2) 4.8.15 emergency use provisions as deemed necessary by the investigator (age ≥18) prior to performing study procedure. aged ≥ 18 years. severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by polymerase chain reaction (pcr) test ≤ 4 days before randomization. currently hospitalized. peripheral capillary oxygen saturation (spo2) ≤ 94% or requiring supplemental oxygen on screening.

inclusion criteria: 1. willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under international conference on harmonization (ich) e6(r2) 4.8.15 emergency use provisions as deemed necessary by the investigator (age ≥18) prior to performing study procedure. 2. aged ≥ 18 years. 3. severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by polymerase chain reaction (pcr) test ≤ 4 days before randomization. 4. currently hospitalized. 5. peripheral capillary oxygen saturation (spo2) ≤ 94% or requiring supplemental oxygen on screening.

inclusion criteria: 1. willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under international conference on harmonization (ich) e6(r2) 4.8.15 emergency use provisions as deemed necessary by the investigator (age ≥18) prior to performing study procedure. 2. aged ≥ 18 years. 3. severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by polymerase chain reaction (pcr) test ≤ 4 days before randomization. 4. currently hospitalized. 5. peripheral capillary oxygen saturation (spo2) ≤ 94% or requiring supplemental oxygen on screening.